Why Low-Dose Naltrexone (LDN) May Be Helpful for Endometriosis: Insights from the Autoimmune Hypothesis LDN Endometriosis - Dr. Kim Integrative Functional Medicine
- Yoon Hang "John" Kim MD
- Sep 26, 2025
- 4 min read
Introduction
Endometriosis is a chronic gynecological disorder characterized by the presence of endometrial-like tissue outside the uterus, affecting approximately 10–15% of women of reproductive age. It often causes pelvic pain, infertility, fatigue, and reduced quality of life.
The autoimmune hypothesis of endometriosis suggests that immune system dysregulation drives disease progression through chronic inflammation, impaired immune surveillance, and autoantibody production. Endometriosis shares biological features with autoimmune diseases, such as elevated cytokine levels, decreased apoptosis of ectopic cells, and immune cell abnormalities.
Within this framework, low-dose naltrexone (LDN)—an opioid receptor antagonist administered at 1–5 mg daily—emerges as a promising immunomodulatory therapy for endometriosis. By enhancing endorphin production and modulating immune activity, LDN may reduce inflammation, balance immune responses, and offer endometriosis pain relief with minimal side effects.
Epidemiological Associations
Studies show that women with endometriosis are more likely to develop autoimmune diseases, including systemic lupus erythematosus, Sjögren’s syndrome (SS), rheumatoid arthritis, thyroid autoimmunity, celiac disease, multiple sclerosis, and inflammatory bowel disease.
For example, one nationwide cohort found an adjusted hazard ratio of 1.45 for developing SS following endometriosis, with the highest risk in younger women within the first five years post-diagnosis. These findings strengthen the concept of autoimmune endometriosis, though limitations like selection bias and small sample sizes remain.
Given LDN’s success in reducing inflammation in autoimmune diseases, exploring LDN for endometriosis treatment is a logical next step.
Genetic and Immunological Mechanisms
Genetic research shows overlapping variants between endometriosis and autoimmune diseases, suggesting shared mechanisms of immune dysfunction.
Key immune abnormalities in endometriosis include:
Altered macrophage, NK cell, and dendritic cell activity.
Elevated pro-inflammatory cytokines (IL-6, IL-8, TNF-α, TGF-β).
Dysregulated complement activation.
Reduced NK cell cytotoxicity and abnormal immune checkpoint activity (PD-1, CTLA-4).
These mechanisms support the idea that endometriosis is not only a hormonal disease but also an immune-driven condition.
How LDN works:
Temporarily blocks opioid receptors.
Causes rebound increases in endorphins and enkephalins.
Reduces glial cell activation and inflammatory cytokines.
Enhances immune tolerance and may improve fertility outcomes.
This dual action—immune modulation and pain reduction—positions LDN as a natural treatment option for endometriosis beyond standard hormonal therapies.
LDN as a Therapeutic Option
Unlike high-dose naltrexone used for addiction, LDN at low doses (1–5 mg) stimulates endorphins and calms inflammation with a favorable safety profile.
Preliminary evidence suggests:
Reduced pelvic pain and inflammation in endometriosis patients.
Symptom improvement in related immune conditions such as fibromyalgia and multiple sclerosis.
No suppression of ovulation, making it a potential fertility-friendly treatment for endometriosis.
Safe use during pregnancy, making it attractive for women pursuing conception.
An ongoing clinical trial is investigating LDN combined with hormonal therapy, with hopes it will improve pain and overall well-being in endometriosis patients.
For many, LDN could serve as a low-cost, low-risk complementary treatment alongside surgery, hormonal suppression, and lifestyle changes.
Limitations and Future Directions
Despite promising results, more research is needed. Most studies on LDN for endometriosis are case reports or small pilot trials. Large-scale randomized controlled trials are required to establish long-term safety, effectiveness, and best dosing strategies.
Future directions include:
Targeted immunotherapies such as complement inhibitors and cytokine blockers.
Exploring the role of the gut microbiome and extracellular vesicles in immune regulation.
Developing personalized treatment plans integrating LDN, diet, surgery, and hormonal therapy.
Conclusion
The autoimmune hypothesis reframes endometriosis as an immune-mediated disorder, not just a hormonal condition. Epidemiological, genetic, and immunological data support this perspective, creating opportunities for new therapies.
Low-dose naltrexone (LDN) offers a novel, safe, and affordable option for endometriosis symptom relief by reducing inflammation and restoring immune balance. While more research is essential, early evidence suggests that LDN may play a key role in future natural and integrative treatment strategies for endometriosis.
Edited by Yoon Hang Kim MD MPH
At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.
References
Abramiuk, M., Grywalska, E., Małkowska, P., Sierawska, O., Hrynkiewicz, R., & Niedźwiedzka-Rystwej, P. (2022). The role of the immune system in the development of endometriosis. Cells, 11(13), Article 2028. https://doi.org/10.3390/cells11132028
Agostinis, C., Balduit, A., Mangogna, A., Zito, G., Romano, F., Ricci, G., Kishore, U., & Bulla, R. (2021). Immunological basis of the endometriosis: The complement system as a potential therapeutic target. Frontiers in Immunology, 11, Article 599117. https://doi.org/10.3389/fimmu.2020.599117
Chao, Y.-H., Liu, C.-H., Pan, Y.-A., Yen, F.-S., Chiou, J.-Y., & Wei, J. C.-C. (2022). Association between endometriosis and subsequent risk of Sjögren’s syndrome: A nationwide population-based cohort study. Frontiers in Immunology, 13, Article 845944. https://doi.org/10.3389/fimmu.2022.845944
Garmendia, J. V., De Sanctis, C. V., Hajdúch, M., & De Sanctis, J. B. (2025). Endometriosis: An immunologist’s perspective. International Journal of Molecular Sciences, 26(11), Article 5193. https://doi.org/10.3390/ijms26115193
Golianovskyi, O. V., Andrienko, O. O., Furman, O. V., & Boyle, P. (2020). Prospective of low dose naltrexone use in treatment of autoimmune pathology and endometriosis. Reproductive Endocrinology, (55), 53–57. https://doi.org/10.31770/2308-3697-2020-55-53-57
Matarese, G., De Placido, G., Nikas, Y., & Alviggi, C. (2003). Pathogenesis of endometriosis: Natural immunity dysfunction or autoimmune disease? Trends in Molecular Medicine, 9(5), 223-228. https://doi.org/10.1016/S1471-4914(03)00051-0
Shigesi, N., Kvaskoff, M., Kirtley, S., Feng, Q., Fang, H., Knight, J. C., Missmer, S. A., Rahmioglu, N., Zondervan, K. T., & Becker, C. M. (2019). The association between endometriosis and autoimmune diseases: A systematic review and meta-analysis. Human Reproduction Update, 25(4), 486-503. https://doi.org/10.1093/humupd/dmz014
Symanska, J., & Czarnocki, K. J. (2021). Immunology and immunotherapy of endometriosis. Journal of Clinical Medicine, 10(24), Article 5879. https://doi.org/10.3390/jcm10245879
Viganò, P., Candiani, M., Monno, A., Giacomini, E., Vercellini, P., & Somigliana, E. (2012). Is there an association between autoimmunity and endometriosis? Autoimmunity Reviews, 11(11), 806-814. https://doi.org/10.1016/j.autrev.2012.01.005
Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2
Comments